Abstract
Goals of therapy for inflammatory bowel disease have advanced beyond symptom control to the normalization of biomarkers of inflammation, and mucosal healing in particular, with the expectation that this will change the natural history of these diseases. Concurrent with higher treatment expectations has come an expanded therapeutic armamentarium to achieve these goals, and a greater ability to optimize each therapeutic class to maximize therapeutic benefits and minimize unnecessary treatment failures. In addition to these advances has come the evolution of therapeutic drug monitoring which is increasingly being utilized to optimize the use of immunomodulators and biologic therapies in particular. This review will outline the principals of optimization of the conventional medical therapies available to the clinician today.
Keywords: Aminosalicylates, allopurinol, anti-tumor necrosis factor agents, corticosteroids, thiopurines, thioguanine nucleotides, therapeutic drug monitoring.
Current Drug Targets
Title:Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014
Volume: 15 Issue: 11
Author(s): Anil Kumar Asthana, Miles P. Sparrow and Laurent Peyrin-Biroulet
Affiliation:
Keywords: Aminosalicylates, allopurinol, anti-tumor necrosis factor agents, corticosteroids, thiopurines, thioguanine nucleotides, therapeutic drug monitoring.
Abstract: Goals of therapy for inflammatory bowel disease have advanced beyond symptom control to the normalization of biomarkers of inflammation, and mucosal healing in particular, with the expectation that this will change the natural history of these diseases. Concurrent with higher treatment expectations has come an expanded therapeutic armamentarium to achieve these goals, and a greater ability to optimize each therapeutic class to maximize therapeutic benefits and minimize unnecessary treatment failures. In addition to these advances has come the evolution of therapeutic drug monitoring which is increasingly being utilized to optimize the use of immunomodulators and biologic therapies in particular. This review will outline the principals of optimization of the conventional medical therapies available to the clinician today.
Export Options
About this article
Cite this article as:
Asthana Kumar Anil, Sparrow P. Miles and Peyrin-Biroulet Laurent, Optimizing Conventional Medical Therapies in Inflammatory Bowel Disease in 2014, Current Drug Targets 2014; 15 (11) . https://dx.doi.org/10.2174/1389450115666140915113503
DOI https://dx.doi.org/10.2174/1389450115666140915113503 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design and Development of Nanovehicle-Based Delivery Systems for Preventive or Therapeutic Supplementation with Flavonoids
Current Medicinal Chemistry Impact of Mixed Nonionic Surfactants on Self-Nanoemulsification Efficiency of Sefsol-218 in Glibenclamide Nanoemulsion
Current Nanoscience Non Peptidic Urotensin II Antagonists: Perspectives for a New Class of Drugs
Cardiovascular & Hematological Agents in Medicinal Chemistry Development, Optimization and in vitro-in vivo Evaluation of Pioglitazone- Loaded Jackfruit Seed Starch-Alginate Beads
Current Drug Delivery Herbal Medicine for Slowing Aging and Aging-associated Conditions: Efficacy, Mechanisms and Safety
Current Vascular Pharmacology Metallocarboxypeptidases: Emerging Drug Targets in Biomedicine
Current Pharmaceutical Design Editorial: Natural Compounds and Their Derivatives as a Source of Promising Drugs for Diabetes and Insulin Resistance
Current Drug Targets COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews Intravitreal Triamcinolone in Diabetic Retinopathy
Current Diabetes Reviews Development of Bilayer Tablet Containing Saxagliptin Immediate Release and Metformin Sustained Release Using Quality by Design Approach
Current Drug Therapy Preparation and Characterization of Glipizide Loaded Eudragit Microparticles
Micro and Nanosystems Metabolomic and Imaging: A Literature Review
Current Medical Imaging The Clinical Significance of IGF-I in Maternal Serum During Pregnancy in Type 1 Diabetes
Current Diabetes Reviews Rosuvastatin Ameliorates Obesity and Proteinuria in Zucker Diabetic Fatty Rats
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The PIK3CA Gene as a Mutated Target for Cancer Therapy
Current Cancer Drug Targets Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?
Current Pharmaceutical Biotechnology The Role of Obesity in the Development of Polycystic Ovary Syndrome
Current Pharmaceutical Design Bitropic D3 Dopamine Receptor Selective Compounds s Potential Antipsychotics
Current Pharmaceutical Design Pharma-metabolomics in Neonatology: is it a Dream or a Fact?
Current Pharmaceutical Design Effect of Soy Isoflavone Supplementation on Endothelial Dysfunction and Oxidative Stress in Equol-Producing Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets